Triplet regimens combining epigenetic unlocking (hypomethylating agents, HMAs), differentiation release (IDH inhibition), and apoptosis priming (BCL-2 blockade) have shown promise in early trials, with a 2024 study reporting CR rates of 50% in IDH-mutant AML with ivosidenib + venetoclax + azacitidine (Lachowiez et al., 2023; Marvin-Peek et al., 2024). Here, IDH1 is linked to acute myeloid leukemia.